Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2023 | Post-hoc analysis of C017: efficacy and safety of cenobamate

Christian Brandt, MD, Bielefeld University, Bielefeld, Germany, discusses a post-hoc analysis of data from the CO17 trial, focusing on seizure-free days in epilepsy management and cenobamate’s efficacy in treating drug-refractory focal epilepsy. They found that seizure-free days remained consistently high during the open-label extension, regardless of other medications. Even patients who had failed multiple antiseizure medications before the trial experienced significant improvements in seizure-free days. Cenobamate effectively reduces the daily burden of seizures in these patients, improving their quality of life. This interview took place at the European Academy of Neurology (EAN) 2023 Congress in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Christian Brandt reports the following disclosures: Honoraria for speaking or consulting activities from Angelini, Eisai, Equilibre, GW Pharmaceuticals, Jazz Pharmaceuticals, Johnson&Johnson, Marinus, UCB Pharma, Xenon and Zogenix.